At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 89 enrolled
Drug / intervention
LY2228820 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of an Oral p38 MAPK Inhibitor in Patients With Advanced Cancer
In Brief
A Phase 1 clinical trial evaluating LY2228820, Midazolam, and 1 other intervention for Advanced Cancer. Completed, enrolled 89 participants across 2 sites.
Detailed Summary
The objective of this study is to determine a safe dose of LY2228820 that may be given to participants with advanced cancer. Part A of this study will consist of dose escalation, and Part B will consist of dose confirmation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedJul 2011
Primary CompletionFeb 2013
Study CompletionDec 2013
TodayJul 2026
First PostedJul 14, 2011
Enrollment StartSep 4, 2008
Primary CompletionFeb 1, 2013
Study CompletionDec 14, 2013
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 15.0 years ago
Interventions
LY2228820drug
Administered orally
Midazolamdrug
Tamoxifendrug